Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	March 21, 2011 May 07, 2012, November 18, 2015

KAPVAY® (clonidine hydrochloride) extended-release tablets

LENGTH OF AUTHORIZATION:

- INITIAL THERAPY – UP TO THREE MONTHS
- CONTINUATION OF THERAPY – UP TO SIX MONTHS

REVIEW CRITERIA:

- Patient must be ≥ 6 years old
- Must have a diagnosis of attention deficit hyperactivity disorder **AND**
- Minimum trial of one month of a methylphenidate (i.e. Daytrana, Focalin XR, Metadate) and amphetamine (i.e. Vyvanse, dextroamphetamine . . .) product. **(If stimulant therapy contraindicated no methylphenidate or amphetamine trial required.) AND**
- Minimum trial of one month of guanfacine, extended release tablet.

DOSING:

- Dosing should be initiated with one 0.1 mg tablet at bedtime, and the daily dosage should be adjusted in increments of 0.1 mg/day at weekly intervals until the desired response is achieved. Doses should be taken twice a day, with either an equal or higher split dosage being given at bedtime, as depicted below

- Do not substitute for other Clonidine products on a mg-per-mg basis, due to differing pharmacokinetic profiles.

- When discontinuing, taper the dose in decrements of no more than 0.1mg every 3 to 7 days.

- Not to be taken concomitantly with any other clonidine products.

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	March 21, 2011 May 07, 2012, November 18, 2015

- **Maximum Dosage Limits:**

•Adults

2.4 mg/day PO immediate-release tablets

•Geriatric

2.4 mg/day PO immediate-release tablets

•Adolescents

0.4 mg/day PO Kapvay extended-release tablets

•Children

>= *6 years:* 0.4 mg/day PO Kapvay extended-release tablets

< *6 years:* Safety and efficacy have not been established.